Pacific's History

November 2011, the Company's common shares began trading on the Canadian National Stock Exchange.

October 2011, as per the Company's articles the class B preferred shares series 1 automatically converted to 1,500,000 common shares. The outstanding class b preferred shares series 1 shares were cancelled.

October 2011, as per the Company's articles the class B preferred shares series 2 automatically converted to 1,791,564 common shares. The outstanding class B preferred shares series 2 shares were cancelled.

October 2011, the Company became a reporting issuer in British Columbia.

October 2011, the Company received its conditional listing letter from the Canadian National Stock Exchange.

July 2011, the Company settled $16,500 of accounts payable to service providers by issuing 110,000 shares at a deemed value of $0.15 per share.

July 2011, the Company's CEO subscribed for 50,000 common shares at $0.15 per share for total proceeds of $7,500.

May 2011, investors subscribed for $75,000 in Irrevocable Subscription Agreements. As a bonus the Company issued 150,000 Class A common shares based on 20% of the principal value of the subscription and a deemed price per share of $0.15. The Company also issued 600,000 common share purchase warrants with an exercise price of $0.15 per warrant and a term of 2 years.

February 2011, the Company entered into the IntelGenx Development and Commercialization Agreement. This agreement supersedes the letter of intent between the companies. The agreement calls for the companies to collaborate in the formulation and bio-equivalency testing of PTL-202. The completion of this work will be a significant milestone for PTL-202 as it will include data from human testing. This data may provide the information required to decide to move PTL-202 in to further clinical testing.

February 2011, 300,000 Class A common shares controlled by a company controlled by the Company's CEO were re-priced from the post split subscription price of $0.00067 per share to $0.02 per share for total proceeds of $5,800.

February 2011, the Company completed a private placement of 60,000 units at $0.15 per unit. Each unit comprises of one common share and one warrant to purchase one common share at $0.25 per share exercisable for a period of 2 years.

February 2011, the Company received a further $25,000 in subscription funds for Irrevocable Subscription Agreements. As a bonus, the Company issued 50,000 Class A common shares based on 20% of the principal value of the subscription and a deemed price per share of $0.15. The Company also issued 200,000 common share purchase warrants with an exercise price of $0.15 per warrant and a term of 2 years.

January 2011, the Company received $275,000 in subscription funds for Irrevocable Subscription Agreements. As a bonus, the Company issued 550,000 Class A common shares based on 20% of the principal value of the subscription and a deemed price per share of $0.15. The Company also issued 2,200,000 common share purchase warrants with an exercise price of $0.15 per warrant and a term of 2 years.

January 2011, 300,000 common share purchase warrants were exercised, and 300,000 common shares were issued, for total proceeds of $30,000.

January 2011, the Company completed a private placement of 140,000 units at $0.15 per unit. Each unit comprises of one common share and one warrant to purchase one common share at $0.25 per share exercisable for a period of 2 years.

January 2011, the Company repriced 4,800,000 Class A common shares, consisting of 4,500,000 Class A common shares originally issued for proceeds of $0.0133 per share to $0.02 per share, for which total proceeds of $30,000 was received, as a result of the repricing an additional 300,000 Class A common shares originally issued for proceeds of $0.0007 per share to $0.02 per share, the Company received total proceeds of $5,800.

December 2010, the Issuer split its equity to 1.5 new shares for each existing share.

November 2010, entered into letter of intent with IntelGenx Corp. for the development and commercialization of PTL-202.

During the 2010, in order to meet CNSX listing requirements, the founders of the Issuer re-priced 3,000,000 Common Shares of the Issuer with an initial subscription price of $0.001 per share to $0.02 per share for total proceeds of $57,000.

During 2010, the Issuer issued 404,000 pre-split Common Shares (606,000 post-split Common Shares) for a total of $95,500.

April 2010, entered into national phase of patent prosecution for PTL-202.

August 2010, closed financing by way of offering memorandum increasing the public shareholder base above the 150 shareholders needed to list the IssuerÕs shares on the CNSX.

January 2010, the Issuer amended the Dalhousie License Agreement.

January 2010, engaged Biopharmaceutical Research Inc. to develop assay for Pentoxifylline and N-Acetylcysteine.

November 2009, closed a financing of $250,800 under offering memorandum dated September 15, 2009.

November 2009, Dr. Wendi Rodrigueza joined the Issuers Board of Directors.

October 2009, Filed a PCT patent application covering the composition of matter and method of use of PTL-303.

July 2009, Dr. Daryl Knight joined Pacific's Scientific Advisory Board.

April 2009, received positive letter on the validity of the PTL-202 patent from the World Intellectual Property Organization.